PRCT was the top-ranked healthcare name in a 9,885-name universe on a +53.7pp valuation margin against a 60.1% 'demonstrated' CAGR. That CAGR is the FY22-FY25 three-year lookback. The business grew 20.2% last quarter, its recurring handpiece line grew 16.2%, and it guides 27-33%. Management disclosed on 2026-02-25 that handpiece unit sales had historically run 8-16% ahead of actual procedures on end-of-quarter bulk discounts, and eliminated the practice. Separately, procedures per installed system have been flat at 67-71 per year for three years, so consumable growth is linear in placements rather than compounding. The valuation margin survives all of it: at an unchanged 2.6x sales multiple and no margin assumption, the price requires 11.0% revenue growth for five years.
How to read this
This is an analysis, not a position. The memo scores every Criteria and blocks on none of them. Whether an analysis justifies a position is a question about a particular book, and two books answer it differently — so this page carries no Long, Short, Watchlist or Avoid verdict.
Every Criteria returns PASS / FAIL / INDETERMINATE, and carries a type. BINDING criteria are admission tests for a long-only absolute-return strategy. MEASURED criteria are always scored and stored and never block. A missing input is INDETERMINATE, never FAIL.
Two valuation outputs, over two horizons. The implied-path test (reverse DCF) asks what today's price requires over five years and whether the business has demonstrated it; the 12-month target asks what the name is likely to trade at, on near-term guidance and the name's own multiple history. Sensitivity is run over the exit multiple, never over scenario probabilities.
Momentum is entry timing only. It governs when to enter a position the thesis already justifies, never whether to own one.
Criteria
| Criteria | Type | Result |
|---|---|---|
| Quality | BINDING | PASS |
| Valuation | BINDING | PASS |
| Downside | MEASURED | logged |
| Liquidity | BINDING | PASS (equity) / PASS AT SMALL SIZE ONLY (options) |
| Momentum | MEASURED | deeply negative — timing headwind |
| Catalyst | MEASURED | PASS — one dominant dated event six days out |
| Consensus | MEASURED | INDETERMINATE |
| Short Mechanism | MEASURED | does not qualify |
| Peer Spread | MEASURED |
Key findings
- The screen's 60.1% 'demonstrated CAGR' is a FY22-FY25 three-year lookback. The business grew 20.2% last quarter and guides 27-33%; Q4'25 grew 11.9% and fell 8.3% sequentially.
- The recurring line — handpieces and other consumables, 59.4% of revenue — grew 16.2% in Q1'26, down from 60.0% in 9M'25.
- Management disclosed and eliminated an end-of-quarter bulk-discount practice that had run handpiece unit sales 8-16% ahead of actual procedures. Q4'25: procedures +69%, handpieces sold +7%.
- Procedures per installed system have been flat at 67-71 per year for three years. The installed base does not compound; consumable growth is linear in placements, and placements grew 12% in FY25 and 12% in Q1'26.
- Q1'26 US procedures were 12,200 — identical to Q4'25 — while the installed base grew 17% across the two quarters. Procedures per system fell 17.8 to 16.5.
- FY26 guidance needs 39-48% US procedure growth; Q1'26 annualises to +12.7%, and FY2025's own seasonal share implies ~+31%, below the guidance floor.
- Reimbursement is RESOLVED, not pending: Category I CPT 52597 live 1 Jan 2026 at ~$540, with APC 5377 opening an ASC pathway. The largest available structural upgrade landed in the very year growth decelerated to 20%.
- Operating-margin expansion stalled: +0.5pp in Q1'26 against the +11.2pp step FY26 guidance implies. Opex grew 20.9% against revenue growth of 20.2%.
- Operating cash burn re-accelerated: Q1'26 alone -$38.1m vs FY2025's full-year -$49.0m.
- Adjusted EBITDA excludes $47.6m of FY25 SBC (15.5% of revenue) and $59m guided for FY26. The FY26 GAAP net-loss guide is -$78.5m to -$91.5m against an adjusted-EBITDA guide of -$17m to -$30m.
- Balance-sheet ratios are clean and stable — DSO 103 vs 102 days, inventory 244 vs 245 days. An AAOI-style DSO screen would have found nothing here.
- Despite all of it the Valuation Criteria PASSES: at an unchanged 2.6x sales multiple and no margin assumption, today's price requires 11.0% revenue growth for five years, against 16.2% on the recurring line alone.
- The stock is -81.8% from its 2024-12-04 all-time high and trades at the 0.45th percentile of its own 1,107-session EV/Sales history.
Sections
Disclosed limitations
- The system TAM denominator is not disclosed. PRCT sizes the patient market ($30bn, 8.0m patients) but discloses no count of target US urology sites. With 765 US systems placed, whether that is 15% or 60% of the reachable site TAM is unknowable from the filings — and it is the key input to whether +12% placement growth is early-innings or saturation.
- The dollar size of the remaining field-inventory overhang is not disclosed. 'A little over one month to seven weeks' of customer inventory and a ~95% handpiece:procedure ratio bound it only loosely.
- Consensus estimates unavailable — Alpha Vantage 25/day shared quota exhausted. Consensus Criteria is INDETERMINATE and blocks nothing.
- No WATER IV readout date, interim-analysis date or enrolment-completion date is disclosed anywhere. None is asserted.
- Q2'26 results are not filed. Everything forward in this memo is company guidance plus arithmetic, and 4 August settles it.
- The screen's 22.8x exit multiple carries peer n=97 on a GROWTH_MATCHED basis, but the constituent list is not in the screen record and could not be re-derived. The Valuation section therefore leans on a sales-basis cross-check anchored on PRCT's own current multiple, which needs no peer set.
- Securities class actions were filed in July 2026 but no 8-K disclosing them had been filed as of 2026-07-28; no damages estimate exists and none is modelled.
- Net cash and share count at the 2027-07-31 target date are house estimates, not disclosures.
- The FY2024 and FY2025 10-Ks contain no revenue disaggregation note. The system/consumable split had to be assembled from 10-Qs and 8-K exhibits.
- The mention-frequency corpus is quarterly press releases, not call transcripts. The two are not interchangeable and the distinction is stated rather than implied.
Defects found while building this memo
- SEC companyfacts retains only the latest filing that restated a prior fiscal year, so a Q4 derived from a 10-K inherits that much later filing date. Used as a point-in-time 'publicly known from' date it pushed every TTM window containing a Q4 years forward and produced EV/Sales medians of 50-120x — confidently wrong, silently. Fixed by falling back to the actual reporting lag when the recorded filing date exceeds 100 days after period end.
- A four-quarter TTM window spans ~274 days between first and last PERIOD END, not ~365. A validity check written as 330 <= span <= 400 rejected every valid window and admitted the single invalid one that skipped a quarter.
- The metrics that decide this thesis — procedures, handpieces sold, install base, handpiece ASP — exist only in 8-K Exhibit 99.1 tables and are not in XBRL. No XBRL-driven screen can see the utilisation flatness or the handpiece:procedure gap. This is the strongest evidence in the record for why Tier 2 exists.